A Phase 2/3 interventional study of Acacia Senegal and Pectin in COVID 19, sponsored by Al-Neelain University. Status unknown at 2 sites in Sudan. Open to participants aged 5 Years to 90 Years. Per ClinicalTrials.gov, last updated 2020-05-12.
Sponsored by Al-Neelain University · Phase 2/3, Interventional, and Treatment
To study the efficacy of Gum Arabic as an immuno modulator and anti-inflammatory agent among COVID 19 seropositive patients..Half of participants will receive Gum Arabic and the other half will receive placebo
Randomized placebo controlled trial including COVID 19 seropositive patients will be treated with 30 gram per day for 4 weeks, compared to placebo group treated for the same duration in positive COVID 19 patients.
Blood samples will be taken first at base line level, after two weeks and after the intervention after satisfying the inclusion and exclusion criteria. The main objective is to assess the effect of Gum Arabic (acacia Senegal) on immune system among COVID-19 patients. The outcome of this project understand SARS-CoV-2 immune response in COVID patients and the effect of Gum Arabic (Acacia Senegal) consumption to counteract progression of the disease
7,990 studies on the registry are indexed under COVID-19; 466 are open to participants now.
This study's planned enrollment of 110 is close to the median of 102 across 4,364 interventional studies indexed under COVID-19.
Browse COVID-19 studies →Al-Neelain University is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
This arm will receive 100% natural Gum Arabic provided in a powder form in 30-grams-dose
Dietary Supplement: Acacia Senegal
This group will be provided with pectin powder provided as one-gram-dose
Dietary Supplement: Pectin
Oral Digestion of Gum Arabic to be consumed early morning on daily basis for 4weeks
Also known as: Gum Arabic
Oral Digestion of Pectin to be consumed early morning on daily basis for 12 weeks
Mean change from baseline score of Immune Response to end of the trial ( Time Frame: up to 4 weeks )
Changes of the level of Tumor Necrosis Factor (TNF), interleukin IL8,IL6,IL10 from the baseline values
Time frame: 4 weeks
Mortality rate
The percentage of deaths among COVID 19 patients received Gum Arabic compared to placebo
Time frame: from the date of assignment until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to two months
Determine viral load in each patient
Change of viral load from Baseline
Time frame: 4 weeks
clinical improvement and hospital discharge
Time of discharge from hospital after full recovery
Time frame: from the date of assignment until the date of hospital discharge for the last assigned case, whichever comes first, assessed up to two months
Plan to share: No
Start is estimated for Jun 2020; primary completion for Aug 2020, 2 months later.
Of 95 non-industry phase 2/3 interventional studies under COVID-19, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 22. This study's planned 2 months is below that.
Counting every sponsor, half of 168 studies reached it within 11 months; a quarter within 5 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in May 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Al-Neelain University